Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Breast cancer research and treatment - 1 Aug 2014

Arthur L M, Turnbull A K, Renshaw L, Keys J, Thomas J S, Wilson T R, Lackner M R, Sims A H, Dixon J M

Abstract excerpt

The phosphatidylinositol-3-kinase pathway plays an important role in proliferation, migration and survival in breast cancer and may play a role in resistance to endocrine therapy. Pathway activation occurs as a result of mutations in PIK3CA or loss of functional PTEN. Matched primary and recurrent samples from 120 breast cancer patients treated with endocrine therapy were profiled with a qPCR-based mutation assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Carcinoma, Ductal, Breast

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Intraductal, Noninfiltrating

Share to Carcinoma, Lobular

Share to Class I Phosphatidylinositol 3-Kinases

Share to Neoplasms, Hormone-Dependent

Share to Neoplasms, Second Primary

Share to Phosphatidylinositol 3-Kinase

Source

Identifiers

PMID: 25104442
DOI: 10.1007/s10549-014-3080-x

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.PMID 25104442Read ↗

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.Semantic proximity Read ↗

PIK3CA mutations in endocrine-resistant breast cancer.Semantic proximity Read ↗

PIK3CA-mutations in breast cancer.Semantic proximity Read ↗

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.Semantic proximity Read ↗

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.Semantic proximity Read ↗

Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer.Semantic proximity Read ↗

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinomaSemantic proximity Read ↗

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Semantic proximity Read ↗

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2- Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia.Semantic proximity Read ↗

Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.Semantic proximity Read ↗

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.Semantic proximity Read ↗

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.